Advanced search
Publication Cover
Expert Opinion on Pharmacotherapy Volume 6, 2005 - Issue 15
Submit an article Journal homepage
62
Views
11
CrossRef citations to date
0
Altmetric
Review

Dopamine agonists for the treatment of restless legs syndrome

Stephany Fulda Max Planck Institute of Psychiatry, Kraepelinstrasse 10, D-80804 Munich, Germany. [email protected]
&
Thomas C Wetter Max Planck Institute of Psychiatry, Kraepelinstrasse 10, D-80804 Munich, Germany. [email protected]
Pages 2655-2666 | Published online: 30 Nov 2005

Bibliography

  • WALTERS AS, THE INTERNATIONAL RESTLESS LEGS SYNDROME STUDY GROUP: Toward a better definition of the restless legs syndrome. Mov. Disord. (1995) 10:634–642.
  • •Established criteria of the International Restless Legs Study Group for the diagnosis of restless legs syndrome.
  • ALLEN RP, PICCHIETTI D, HENING WA, TRENKWALDER C, WALTERS AS, MONTPLAISIR J: Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology. A report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health. Sleep Med. (2003) 4:101–119.
  • •Survey on all aspects of restless legs syndrome, including modified diagnostic criteria and criteria for augmentation.
  • PHILLIPS B, YOUNG T, FINN L, ASHER K, HENING WA, PURVIS C: Epidemiology of restless legs symptoms in adults. Arch. Intern. Med. (2000) 160:2137–2141.
  • MASOOD A, PHILLIPS B: Epidemiology of restless legs syndrome. In: Sleep and Movement Disorders. Chokroverty S, Hening WA, Walters AS (Eds), Butterworth Heinemann, Philadelphia (2003):316–321.
  • ROTHDACH AJ, TRENKWALDER C, HABERSTOCK J, KEIL U, BERGER K: Prevalence and risk factors of RLS in an elderly population. The MEMO Study. Neurology (2000) 54:1064–1068.
  • SEVIM S, DOGU O, CAMDEVIREN H et al.: Unexpectedly low prevalence and unusual characterstics of RLS in Mersin, Turkey. Neurology (2003) 61:1562–1569.
  • TAN EK, SEAH A, SEE SJ, LIM E, WONG MC, KOH KK: Restless legs syndrome in an Asian population: a study in Singapore. Mov. Disord. (2001) 16:577–578.
  • TRENKWALDER C, PAULUS W: Why do restless legs occur at rest? - pathophysiology of neuronal structures in RLS. Neurophysiology of RLS (part 2). Clin. NeurophysioL (2004) 115:1975–1988.
  • •In-depth review of the neuronal structures relevant to the pathophysiology of restless legs syndrome.
  • ALLEN RP, EARLEY CJ: Restless legs syndrome: a review of clinical and pathophysiological features. J. Clin. NeurophysioL (2001) 18:128–147.
  • WETTER TC, EISENSEHR I, TRENKWALDER C: Functional neuroimaging studies in restless legs syndrome. Sleep Med. (2004) 5:401–406.
  • •Comprehensive review of neuroimaging studies in restless legs syndrome.
  • ALLEN R: Dopamine and iron in the pathophysiology of restless legs syndrome (RLS). Sleep Med. (2004) 5:385–391.
  • •Review of the role of iron and dopamine in the pathophysiology of restless legs syndrome.
  • KRIEGER J, SCHROEDER C: Iron, brain and restless legs syndrome. Sleep Med. Rev. (2001) 5:277–286.
  • LAZZARINI A. WALTERS AS, HICKEY K et al.: Studies of penetrance and anticipation in five autosomal-dominant restless legs syndrome pedigrees. Mov. Disord. (1999) 14:111–116.
  • WINKELMANN J, MOLLER-MYHSOK B, WITTCHEN HU et aL: Complex segregation analysis of restless legs syndrome provides evidence for an autosomal dominant mode of inheritance in early age at onset families. Ann. Neurol. (2002) 52:297–302.
  • •The first large segregation analysis in restless legs syndrome demonstrating differences in the mode of inheritance between early versus late age at onset families.
  • BANNO K, DELAIVE K, WALLD R, KRYGER MH: Restless legs syndrome in 218 patients: associated disorders. Sleep Med. (2000) 1:221–229.
  • RIJSMAN RM, DE WEERD AW: Secondary periodic limb movement disorder and restless legs syndrome. Sleep Med. Rev. (1999) 3:147–158.
  • THE INTERNATIONAL RESTLESS LEGS SYNDROME STUDY GROUP: Validation of the International Restless Legs Syndrome Study Group rating scale for restless legs syndrome. Sleep Med. (2003) 4:121–132.
  • •Validated data on the rating scale for the severity of restless legs syndrome. The scale is a standard outcome measure in pharmacological studies.
  • TRENKWALDER C, GARCIA-BORREGUERO D, MONTAGNA P et al.: Ropinirole in the treatment of restless legs syndrome: results from the TREAT RLS 1 study, a 12 week, randomised, placebo controlled study in 10 European countries. J. NeuroL Neurosurg. Psychiatry (2004) 75:92–97.
  • WALTERS AS, ONDO WG, DREYKLUFT T, GRUNSTEIN R, LEE D, SETHI K: Ropinirole is effective in the treatment of restless legs syndrome. TREAT RLS 2: a 12-week, double-blind, randomized, parallel-group, placebo-controlled study. Mov. Disord. (2004) 19:1414–1423.
  • HENING WA, ALLEN RP, EARLEY CJ, PICCHIETTI DL, SILBER MH: An update on the dopaminergic treatment of restless legs syndrome and periodic limb movement disorder. Sleep (2004) 27:560–583.
  • •The most recent of the comprehensive reviews of clinical trials published through April 2002, from the American Academy of Sleep Medicine.
  • LITTNER MR, KUSHIDA C, ANDERSON -WM et al.: Practice parameters for the dopaminergic treatment of restless legs syndrome and periodic limb movement disorder. Sleep (2004) 27:557–559.
  • CHESSON AL JR, WISE M, DAVILA D et al.: Practice parameters for the treatment of restless legs syndrome and periodic limb movement disorder. An American Academy of Sleep Medicine Report. Sleep (1999) 22:961–968.
  • SILBER MH, EHRENBERG BL, ALLEN RP et al.: An algorithm for the management of restless legs syndrome. Mayo Clin. Proc. (2004) 79:916–922.
  • •The first restless legs syndrome expert's consensus approach to a clinical algorithm for the treatment of restless legs syndrome.
  • AKPINAR S: Restless legs syndrome treatment with dopaminergic drugs. Clin. Neuropharmacol. (1987) 10(1):69–79.
  • •The first controlled trial of levodopa in restless legs syndrome.
  • BENES' H, KURELLA B, KUMMER J, KAZENWADEL J, SELZER R, KOHNEN R: Rapid onset of action of levodopa in restless legs syndrome: a double-blind, randomized, multicenter, crossover trial. Sleep (1999) 22:1073–1081.
  • BRODEUR C, MONTPLAISIR J, GODBOUT R, MARINIER R: Treatment of restless legs syndrome and periodic movements during sleep with L-dopa: a double-blind, controlled study. Neurology (1988) 38:1845–1848.
  • COLLADO-SEIDMEL V, KAZENWADEL J, WETTER TC et al.: A controlled study of additional sr-L-dopa in L-dopa-responsive restless legs syndrome with late-night symptoms. Neurology (1999) 52:285–290.
  • SALETU M, ANDERER P, HOGL B et aL: Acute double-blind, placebo-controlled sleep laboratory and clinical follow-up studies with a combination treatment of rr-L-dopa and sr-L-dopa in restless legs syndrome. J. Neural Transm. (2003) 110:611–626.
  • TRENKWALDER C, STIASNY K, POLLMACHER T et al.: L-dopa therapy of uremic and idiopathic restless legs syndrome: a double-blind, crossover trial. Sleep (1995) 18:681–688.
  • WALKER SL, FINE A, KRYGER MH: L-DOPA/carbidopa for nocturnal movement disorders in uremia. Sleep (1996) 19:214–218.
  • PELLECCHIA MT, VITALE C, SABATINI M et al.: Ropinirole as a treatment of restless legs syndrome in patients on chronic hemodialysis: an open randomized crossover trial versus levodopa sustained release. Clin. Neuropharmacol. (2004) 27(4):178–181.
  • STAEDT J, WASSMUTH F, ZIEMANN U, HAJAK G, ROTHER E, STOPPE G: Pergolide: treatment of choice in restless legs syndrome (RLS) and nocturnal myoclonus syndrome (NMS). A double-blind randomized crossover trial of pergolide versus L-Dopa. J. Neural Transm. (1997) 104:461–468.
  • ALLEN RP, EARLEY CJ: Augmentation of the restless legs syndrome with carbidopa/ levodopa. Sleep (1996) 19:205–213.
  • •The first description of augmentation during treatment with levodopa.
  • COMMITTEE ON SAFETY OF MEDICINES REPORT UK: Current problems in pharmacovigilance (2002).
  • •Warnings about the occurrence of possible adverse events in the form of pleuropulmonary, cardiac and retroperitoneal fibrosis related to the use of the ergot dopamine agonists bromocriptine, pergolide and cabergoline in Parkinson's disease.
  • MULLER T, FRITZE J: Fibrosis associated with dopamine agonist therapy in Parkinson's disease. Clin. Neuropharmacol. (2003) 26(3):109–111.
  • STIASNY K, ROBBECKE J, SCHULER P, OERTEL WH: Treatment of idiopathic restless legs syndrome (RLS) with the D2-agonist cabergoline-an open clinical trial. Sleep (2000) 23(3):349–354.
  • ZUCCONI M, OLDANI A. CASTRONOVO C, FERINI-STRAMBI L: Cabergoline is an effective single-drug treatment for restless legs syndrome: clinical and actigraphic evaluation. Sleep (2003) 26:815–818.
  • BENES' H, HEINRICH CR, UEBERALL MA, KOHNEN R: Long-term safety and efficacy of cabergoline for the treatment of idiopathic restless legs syndrome: results from an open-label 6-month clinical trial. Sleep (2004) 27:674–682.
  • STIASNY-KOLSTER K, BENES' H, PEGLAU I et al.: Effective cabergoline treatment in idiopathic restless legs syndrome. Neurology (2004) 63:2272–2279.
  • OERTEL WH, BENES' H, HAPPE S, KOHNEN R, LEROUX M, STIASNY-KOLSTER K: Efficacy of cabergoline for the treatment of sensori-motor symptoms and sleep disturbances in restless legs syndrome: a placebo-controlled, 5-week, double-blind, randomized, multicenter, polysomnographic study. Mov. Disord. (2004) 19\(Suppl. 9):5425.
  • TRENKWALDER C, BENES' H, HAPPE S, KOHNEN R, CALDIR S: Results from the first active controlled trial to investigate efficacy of cabergoline compared to levodopa in the treatment of patients with severe restless legs syndrome. Sleep (2005) 28(Abstr. Suppl.):A277.
  • EARLEY CJ, YAFFEE JB, ALLEN RP: Randomized, double-blind, placebo-controlled trial of pergolide in restless legs syndrome. Neurology (1998) 51:1599–1602.
  • TAGAYA H, WETTER TC, WINKELMANN J et al.: Pergolide restores sleep maintenance but impairs sleep EEG synchronization in patients with restless legs syndrome. Sleep Med. (2002) 3:49–54.
  • TRENKWALDER C, HUNDEMER HP, LLEDO A et al.: Efficacy of pergolide in treatment of restless legs syndrome: the PEARLS Study. Neurology (2004) 62:1391–1397.
  • WETTER TC, STIASNY K, WINKELMANN J et al.: A randomized controlled study of pergolide in patients with restless legs syndrome. Neurology (1999) 52:944–950.
  • PIETA J, MILLAR T, ZACHARIAS J, FINE A, KRYGER M: Effect of pergolide on restless legs and leg movements in sleep in uremic patients. Sleep (1998) 21(6):617–622.
  • EARLEY CJ, ALLEN RP: Pergolide and carbidopa/levodopa treatment of the restless legs syndrome and periodic leg movements in sleep in a consecutive series of patients. Sleep (1996) 19:801–810.
  • SILBER MH, SHEPARD JW, JR., WISBEY JA: Pergolide in the management of restless legs syndrome: an extended study. Sleep (1997) 20:878–882.
  • NOEL S, KORRI H, VANDERHEYDEN JE: Low dosage of pergolide in the treatment of restless legs syndrome. Acta Neurol Belg. (1998) 98(1):52–53.
  • STIASNY K, WETTER TC, WINKELMANN J et al: Long-term effects of pergolide in the treatment of restless legs syndrome. Neurology (2001) 56:1399–1402.
  • STAEDT J, HUNERJAGER H, RUTHER E, STOPPE G: Pergolide: treatment of choice in Restless Legs Syndrome (RLS) and Nocturnal Myoclonus Syndrome (NMS). Longterm follow up on pergolide. Short communication. J. Neural Transm. (1998) 105(2-3):265–268.
  • WINKELMANN J, WETTER TC, STIASNY K, OERTEL WH, TRENKWALDER C: Treatment of restless leg syndrome with pergolide - an open clinical trial. Mov. Disord. (1998) 13:566–569.
  • WALTERS AS, HENING WA, KAVEY N, CHOKROVERTY S, GIDRO-FRANK S: A double-blind randomized crossover trial of bromocriptine and placebo in restless legs syndrome. Ann. Neurol (1988) 24:455–458.
  • TERGAU F, WISCHER S, WOLF C, PAULUS W: Treatment of restless legs syndrome with the dopamine agonist alpha-dihydroergocryptine. Mov. Disord. (2001) 16:731–735.
  • EVIDENTE VGH: Piribedil for restless legs syndrome: a pilot study. Mov. Disord. (2001) 16:579–581.
  • BENE8 H: Treatment of the restless legs syndrome with lisuride - results from a pilot study with patch application. J. Sleep Res. (2004) 13\(Suppl. 1):69.
  • INOUE Y, MITANI H, NANBA K, KAWAHARA R: Treatment of periodic leg movement disorder and restless leg syndrome with talipexole. Psychiatry Clin. Neurosci. (1999) 53:283–285.
  • SONKA K, PRETL M, KRANDA K: Management of restless legs syndrome by the partial D2-agonist terguride. Sleep Med. (2003) 4(5):455–457.
  • TRIBL GG, SYCHA T, KOTZAILIAS N, ZEITLHOFER J, AUFF E: Apomorphine in idiopathic restless legs syndrome: an exploratory study. J. Neurol Neurosurg. Psychiatry (2005) 76(2):181–185.
  • REUTER I, ELLIS CM, CHAUDHURI KR: Nocturnal subcutaneous apomorphine infusion in Parkinson's disease and restless legs syndrome. Acta Neurol Scand. (1999) 100:163–167.
  • TINGS T, STIENS G, PAULUS W, TRENKWALDER C, HAPPE S: Treatment of restless legs syndrome with subcutaneous apomorphine in a patient with short bowel syndrome. J. Neurol (2005) 252:361–363.
  • ALLEN R, BECKER PM, BOGAN R et al.: Ropinirole decreases periodic leg movements and improves sleep parameters in patients with restless legs syndrome. Sleep (2004) 27:907–914.
  • TOMPSON D, DELLA PASQUA O: A single-blind, placebo-controlled, forced-titration study of ropinirole in RLS: pharmacokinetic-pharmacodynamic relationships. Sleep (2004) 27(Abstr. Suppl.):A298.
  • KELLY M, MISTRY P: Tolerability of a forced-dose escalating regimen of ropinirole in patients with RLS. Mov. Disord. (2005) 20\(Suppl. 10):563.
  • BOGAN R, CONNOLLY MG, REDERICH G: Ropinirole is an effective, well-tolerated treatment for moderate-to-severe RLS: results of a US study. Mov. Disord. (2005) 20\(Suppl. 10):561.
  • DREYKLUFT T, KARRASCH J, SMUTS J, VOLC D, GRUNSTEIN J, MONTPLAISIR J: The long-term safety and tolerability of ropinirole in RLS. Mov. Disord. (2004) 19\(Suppl. 9):5430.
  • MONTPLAISIR J, KARRASCH J, HAAN J, KRUGER AJ, VOLC D: The impact of ropinirole treatment on RLS symptoms and health-related quality of life (HRQoL) in patients with RLS: results of a multinational 36-week study. Sleep (2004) 27(Abstr. Suppl.):A293.
  • ADLER CH, HAUSER RA, SETHI K et al.: Ropinirole for restless legs syndrome: a placebo-controlled crossover trial. Neurology (2004) 62:1405–1407.
  • BLI WISE DL, FREEMAN k INGRAM CD, RYE DB, CHAKRAVORTY S, WATTS RL: Randomized, double-blind, placebo-controlled, short-term trial of ropinirole in restless legs syndrome. Sleep Med. (2005) 6:141–147.
  • SALETU B, GRUBER G, SALETU M et al.: Sleep laboratory studies in restless legs syndrome patients as compared with normals and acute effects of ropinirole. 1. Findings on objective and subjective sleep and awakening quality. Neuropsychobiology (2000) 41:181–189.
  • SALETU M, ANDERER P, SALETU B et al.: Sleep laboratory studies in restless legs syndrome patients as compared with normals and acute effects of ropinirole. 2. Findings on periodic leg movements, arousals and respiratory variables. Neuropsychobiology (2000) 41:190–199.
  • GALVEZ-JIMENEZ N, KHAN T: Ropinirole and restless legs syndrome. Mov. Disord. (1999) 14:890–892.
  • ESTIVILL E, DE LA FUENTE V: [The use of ropinirol ++ as a treatment for restless leg syndrome.] Rev. Neurol (1999) 28:962–963.
  • ESTIVILL E, DE LA FUENTE V: The efficacy of ropinirole in the treatment of chronic insomnia secondary to restless legs syndrome: polysomnography data. Rev. Neurol (1999) 29:805–807.
  • ONDO W: Ropinirole for restless legs syndrome. Mov. Disord. (1999) 14:138–140.
  • HAPPE S, SAUTER C, KLOSCH G, SALETU B, ZEITLHOFER J: Gabapentin versus ropinirole in the treatment of idiopathic restless legs syndrome. Neuropsychobiology (2003) 48:82–86.
  • DE LA FUENTE-FERNANDEZ R, RUTH TJ, SOSSI V SCHULZER M, CALNE DB, STOESSL AJ: Expectation and dopamine release: mechanism of the placebo effect in Parkinson's disease. Science (2001) 293:1164–1166.
  • BECKER PM, ONDO W, SHARON D: Encouraging initial response of restless legs syndrome to pramipexole. Neurology (1998) 51:1221–1223.
  • FERINI-STRAMBI L: Restless legs syndrome augmentation and pramipexole treatment. Sleep Med. (2002) 3(Suppl.):S23–S25.
  • UN SC, KAPLAN J, BURGER CD, FREDRICKSON PA: Effect of pramipexole in treatment of resistant restless legs syndrome. Mayo Clin. Proc. (1998) 73:497–500.
  • WINKELMAN JW, JOHNSTON L: Augmentation and tolerance with long-term pramipexole treatment of restless legs syndrome (RLS). Sleep Med. (2004) 5:9–14.
  • MANCONI M, CASETTA I, GOVONI CESNIK E, FERINI-STRAMBI L, GRANIERI E: Pramipexole in restless legs syndrome. Evaluation by suggested immobilization test. J. Neurol (2003) 250:1494–1495.
  • MIRANDA M, KAGI M, FABRES L et al:Pramipexole for the treatment of uremic restless legs in patients undergoing hemodialysis. Neurology (2004) 62:831–832.
  • MONTPLAISIR J, DENESLE R, PETIT D: Pramipexole in the treatment of restless legs syndrome: a follow-up study. Eur. J. Neurol. (2000) 7\(Suppl. 0:27–31.
  • SALETU M, ANDERER P, SALETU-ZYHLARZ G, HAUER C, SALETU B: Acute placebo-controlled sleep laboratory studies and clinical follow-up with pramipexole in restless legs syndrome. Arch. Psychiatry Clin. Neurosci. (2002) 252:185–194.
  • SILBER MH, GIRISH M, IZURIETA R: Pramipexole in the management of restless legs syndrome: an extended study. Sleep (2003) 26:819–821.
  • STIASNY K, MOLLER JC, OERTELWH: Safety of pramipexole in patients with restless legs syndrome. Neurology (2000) 55:1589–1590.
  • STIASNY-KOLSTER K, OERTEL WH: Low-dose pramipexole in the management of restless legs syndrome. An open label trial. Neuropsychobiology (2004) 50:65–70.
  • MONTPLAISIR J, NICOLAS A. DENESLE R, GOMEZ-MANCILLA B: Restless legs syndrome improved by pramipexole: a double-blind randomized trial. Neurology (1999) 52:938–943.
  • FANTINI L, DESAUTELS A, MICHAUD M, PETIT D, MONTPLAISIR J: Long-term effects of pramipexole in the treatment of restless legs syndrome. Mov. Disord. (2004) 19\(Suppl. 9):5428.
  • SZAKÁCS Z, KOVES P: Treatment of idiopathic restless legs syndrome (RLS) with the D3-agonist pramipexole. Sleep (2003) 26(Suppl.):A335 (Abstr.).
  • PARTINEN M, HIRVONEN K, ALAKUJALA A, JAMA L, TERTTUNEN J: Pramipexole is safe and efficacious in the treatment of idiopathic restless legs syndrome: results of a large randomized double-blind placebo-controlled dose-finding study. Sleep (2004) 27(Suppl.):A293 (Abstr.).
  • OERTEL W, STIASNY-KOLSTER K: Pramipexole is effective in the treatment of restless legs syndrome (RLS): results of a 6 week, multi-centre, double-blind, and placebo-controlled study. Mov. Disord. (2005) 20\(Suppl. 10):558.
  • TAN EK, ONDO W: Clinical characteristics of pramipexole-induced peripheral edema. Arch. Neurol (2000) 57(5):729–732.
  • STIASNY-KOLSTER K, KOHNEN R, SCHOLLMAYER E, MOLLER JC, OERTEL WH: Patch application of the dopamine agonist rotigotine to patients with moderate to advanced stages of restless legs syndrome: a double-blind, placebo-controlled pilot study. Mov. Disord. (2004) 19:1432–1510.
  • ONDO W, ROMANYSHYN J, VUONG KD, LAI D: Long-term treatment of restless legs syndrome with dopamine agonists. Arch. Neurol (2004) 61:1393-1397. Websites

Websites

  • http://www.fda.gov/medwatch/SAFETY/ 192003/permax.htm USFood and Drug Administration, safety alert (2003). Accessed 31 October, 2005.
  • http://cmgsk.co.uk/Summary/ropinirole/ studylist.asp Ropinirole clinical trial site. Accessed 31 October, 2005.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.